Ophthalmic Eye Dropper Global Market Report 2024

The ophthalmic eye dropper market size has grown strongly in recent years. It will grow from $12.38 billion in 2023 to $13.32 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%. The growth in the historic period can be attributed to enhanced patient convenience, a favorable regulatory environment, the adoption of combination therapies, a shift towards combination therapies, and a preference for self-administered eye care products.

The ophthalmic eye dropper market size is expected to see strong growth in the next few years. It will grow to $17.97 billion in 2028 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to the rising prevalence of eye-related conditions, public health initiatives, the increasing use of precision and individualized medicines, consumer education initiatives, and research and development. Major trends in this period include nanoparticle-based drug formulations, advanced drug delivery systems, an emphasis on innovative drug delivery, collaborative efforts for innovative solutions, and a surge in demand for multi-dose eye droppers.

The anticipated rise in eye disorders is set to drive the expansion of the ophthalmic eye dropper market in the foreseeable future. Eye disorders encompass a wide range of medical conditions affecting the eyes, leading to vision impairment or discomfort. The growing prevalence of these disorders can be attributed to environmental factors, increased contact lens usage, shifts in lifestyle, gender disparities, and deficiencies in essential vitamins. Ophthalmic eye droppers play a crucial role in delivering precise doses of medication directly to the eyes for treating various eye conditions. For example, as of January 2024, the Centers for Disease Control and Prevention reported that over 3.4 million Americans aged 40 and above were either blind or visually impaired, a figure projected to double by 2030. Hence, the escalating prevalence of eye disorders is fueling the expansion of the ophthalmic eye dropper market.

Prominent players in the ophthalmic eye dropper market are concentrating on pioneering solutions, such as antimicrobial ophthalmic droppers, to enhance product efficacy and safety. These droppers, integrated with antimicrobial technology, ensure sterile and hygienic application for eye treatments. For instance, in March 2022, Pylote and Berry Global Group Inc. unveiled an antimicrobial ophthalmic dropper, aiming to introduce the first multidose dropper with antimicrobial protection. This innovative dropper combines Pylote's patented mineral antimicrobial technology with Berry Global's expertise in sustainable healthcare packaging. It incorporates antimicrobial technology at the tip, ensuring hygienic usage with each application, while also reducing plastic waste compared to conventional monodose solutions. Moreover, it remains compatible with existing treatments and packaging processes.

In April 2023, the Nirma Group acquired Stericon Pharma Pvt. Ltd. for an undisclosed sum. This acquisition marks a strategic move by the Nirma Group to leverage synergies between the companies, accessing new markets, technologies, and capabilities. The objective is to strengthen the group's presence in the contract development and manufacturing organization (CDMO) sector, as well as enhance its current healthcare portfolio. Stericon Pharma Pvt. Ltd., an Indian-based pharmaceutical manufacturing company specializing in eye dropper production, brings valuable expertise to the Nirma Group.

Major companies operating in the ophthalmic eye dropper market are Pfizer Inc., AbbVie Inc., Novartis AG, Alcon Inc., Bausch & Lomb Incorporated, Rexam Healthcare Packaging Inc., Intas Pharmaceuticals Ltd., AptarGroup Inc, Cipla Ltd, Gerresheimer AG, Lupin Ltd., Santen Pharmaceutical Co Ltd., Rohto Pharmaceutical Co Ltd., Silgan Dispensing Systems, Akorn Operating Company LLC, Nemera Development S.A., Ajanta Pharma Ltd., Perrigo Company plc, Bora Pharmaceuticals Co Ltd., Sun Pharmaceutical Industries Limited, Flagship Biotech International Private Limited, PanOptica Inc., SAS Yslab.

North America was the largest region in the ophthalmic eye dropper market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ophthalmic eye dropper market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the ophthalmic eye dropper market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

An ophthalmic eye dropper is a medical device specifically designed for administering liquid medication, usually in the form of eye drops, into the eyes. It is used by gently squeezing the bottle to release a drop into the lower eyelid pocket, ensuring precise administration of the medication into the eye.

The main types of ophthalmic eye droppers include unidose eye droppers, preserved multi-dose eye droppers, and preservative-free multi-dose eye droppers. A unidose eye dropper is a single-use, pre-measured container designed to deliver a specific dose of eye drops. Various drugs, including prescription and over-the-counter (OTC) medications, are used to treat conditions such as dry eye, glaucoma, allergies, conjunctivitis, and others, and are utilized in hospitals, ophthalmic centers, homecare settings, and other locations.

The ophthalmic eye dropper research report is one of a series of new reports that provides ophthalmic eye dropper market statistics, including the ophthalmic eye dropper industry's global market size, regional shares, competitors with an ophthalmic eye dropper market share, detailed ophthalmic eye dropper market segments, market trends and opportunities, and any further data you may need to thrive in the ophthalmic eye dropper industry. This ophthalmic eye dropper market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The ophthalmic eye dropper market consists of sales of visine advanced relief, systane ultra lubricant, refresh optical lubricant, clear eyes maximum redness relief, and blink tears lubricating eye drops. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.